CLINICAL TRIALS PROFILE FOR ANAPROX DS

All Clinical Trials for ANAPROX DS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00688961 ↗	Effects of Omacor and Aspirin on Platelet Function	Completed	Sanford Research	Early Phase 1	2007-06-01	Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can affect blood clotting by altering the function of the blood platelets. Aspirin can do the same. The purpose of this study is to determine the individual and combined effects of these two agents on platelet function using a whole blood method.
NCT00778193 ↗	Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers	Completed	Research Associates of New York, LLP	Phase 4	2007-10-01	Gastroduodenal ulcers are extremely common in the community today. Though much has been written and observed concerning how ulcers form, not much has been described in the human model concerning how these ulcers heal. As numerous patients already suffer from gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the treatment and management of these patients. The goal of this study is to investigate the effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal lesions in order to elucidate the mechanisms of ulcer healing. This single site, single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer healing through endoscopic, immunohistologic, and molecular PCR modalities.
NCT01052129 ↗	Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition	Completed	Dr. Reddy's Laboratories Limited	Phase 1	2006-05-01	An open label randomised, two-treatment, two-period, two-sequence, single-dose, crossover, comparative bioequivalence study.
NCT01052792 ↗	Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions	Completed	Dr. Reddy's Laboratories Limited	Phase 1	2006-05-01	An open label randomised, two-treatment,two-period, two-sequence, single-dose, crossover, comparative bioequivalence study.
NCT01442428 ↗	Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial	Withdrawn	Minnesota Medical Foundation	Phase 2/Phase 3	2014-01-01	Tuberculosis is the most common opportunistic infection (OI) in HIV-infected persons worldwide, including in South East Asia. Significant numbers of patients experience tuberculosis-related paradoxical immune reconstitution inflammatory syndrome (TB-IRIS) after ART initiation, yet the optimal treatment of TB-IRIS is unknown. A recent randomized-controlled trial showed the benefit of prednisone over placebo in reduction of days of hospitalization and invasive procedures. The investigators hypothesize that nonsteroidal anti-inflammatory drugs (NSAIDs) are as effective as corticosteroids for treatment of non-life threatening TB-IRIS in HIV-infected patients and hypothesize that adjunctive treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (Statins) may improve the outcomes. This is a randomized controlled trial with a 2x2 factorial design to test the relative benefit of corticosteroids, NSAIDS, and Statins for the symptomatic and immunologic control of TB-IRIS.
NCT01442428 ↗	Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial	Withdrawn	Pfizer	Phase 2/Phase 3	2014-01-01	Tuberculosis is the most common opportunistic infection (OI) in HIV-infected persons worldwide, including in South East Asia. Significant numbers of patients experience tuberculosis-related paradoxical immune reconstitution inflammatory syndrome (TB-IRIS) after ART initiation, yet the optimal treatment of TB-IRIS is unknown. A recent randomized-controlled trial showed the benefit of prednisone over placebo in reduction of days of hospitalization and invasive procedures. The investigators hypothesize that nonsteroidal anti-inflammatory drugs (NSAIDs) are as effective as corticosteroids for treatment of non-life threatening TB-IRIS in HIV-infected patients and hypothesize that adjunctive treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (Statins) may improve the outcomes. This is a randomized controlled trial with a 2x2 factorial design to test the relative benefit of corticosteroids, NSAIDS, and Statins for the symptomatic and immunologic control of TB-IRIS.

Clinical Trial Conditions for ANAPROX DS

Condition Name

Condition Name for ANAPROX DS
Intervention	Trials
Healthy	3
Acute Pain	2
Chronic Low Back Pain	2
Chronic Pain	1

Condition MeSH

Condition MeSH for ANAPROX DS
Intervention	Trials
Back Pain	4
Low Back Pain	3
Acute Pain	2
Acquired Immunodeficiency Syndrome	1

Clinical Trial Locations for ANAPROX DS

Trials by Country

Trials by Country for ANAPROX DS
Location	Trials
United States	7
India	2
Thailand	1

Trials by US State

Trials by US State for ANAPROX DS
Location	Trials
Illinois	5
New York	1
South Dakota	1

Clinical Trial Progress for ANAPROX DS

Clinical Trial Phase

Clinical Trial Phase for ANAPROX DS
Clinical Trial Phase	Trials
Phase 4	5
Phase 2/Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for ANAPROX DS
Clinical Trial Phase	Trials
Completed	6
Withdrawn	3
Unknown status	2

Clinical Trial Sponsors for ANAPROX DS

Sponsor Name

Sponsor Name for ANAPROX DS
Sponsor	Trials
National Institutes of Health (NIH)	6
Northwestern University	5
Dr. Reddy's Laboratories Limited	2

Sponsor Type

Sponsor Type for ANAPROX DS
Sponsor	Trials
Other	14
NIH	10
Industry	5